1. Volume 15, Issue 4, Pages 415-423 (April 2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial 
Prof Ian Judson, MD, Prof Jaap Verweij, PhD, Prof Hans Gelderblom, PhD, Prof Jörg T Hartmann, MD, Prof Patrick Schöffski, MPH, Prof Jean-Yves Blay, PhD, J Martijn Kerst, PhD, Prof Josef Sufliarsky, MD, Prof Jeremy Whelan, MD, Prof Peter Hohenberger, MD, Anders Krarup-Hansen, MD, Prof Thierry Alcindor, MD, Sandrine Marreaud, MD, Saskia Litière, PhD, Catherine Hermans, Prof Cyril Fisher, DSc, Prof Pancras C W Hogendoorn, PhD, Prof A Paolo dei Tos, MD, Prof Winette T A van der Graaf, PhD 
The Lancet Oncology 
Volume 15, Issue 4, Pages (April 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*One of whom started treatment but did not follow the allocated approach.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier curves for overall survival (A) and progression-free survival (B)
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3 Progression-free survival by subgroup
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions